Jetman is accumulating Vical if he's as smart as what I think he may be. More accumulation now than later as the storm settles. Dr. Kus , jetman's friend from the OGXI board did not follow my advice to sell OGXI at $22. Sour , I don't take any of the Isis pumpers serious as 99% have no idea what antisense relates to in medicine. Enjoy the day my friend.
Sour I was concerned about your health and glad you're breathing along with me. A few times I had put feelers out for your ID with no reply and to be honest I thought the worst. I had a nice run with BMY, CELG, AMGN in and out with TASR. Once in a while I pick up a few more shares of Vical in the $1.05 area and hoping for the best. Since late 2013 Vical's IR has not answered my calls or E-mails... there is a reason for same. As of last week the plaintiffs are falling by the way side and of no concern to me. Our group is waiting several years for an isis safe antisense drug to be developed. Antisense compounds remain a problem, liver effects etc. Antisense targeting I have always liked and supported, that's basically where it remains this date. Antisense targeting has been Dr. Crooke's savior as you must know by now. I am selling BMY for dry powder and adding to TASR and increasing cash holdings for pull backs . Hang in there Sour ... so good to hear from you.
You may be right on VJ , however, he is no fool. Vical is working on exciting areas in naked-dna targets. Jet, for 100 cents a Vical share new stockholders own a terrific option on the future . The Isis stock price has discounted their unproven future. Let's hope for the best with both biotechs.
I have to give Dr. Crooke credit for tossing it to Ogxi after Isis had completed a trial with same. Out of 31 Isis patients enrolled the result was no clinical response in all 31. Ogxi's stock price went up very high, as it declined , finally at the $22 area I placed my Strong Sell on Ogxi.
I noticed that the TV personality hyping Isis is quite ignorant with regard to antisense technology.
I maintain all of our Vical shares with good reason ! Remember, there is no sure thing in biotech drug investment.